Chronic hepatitis C
Conditions
Interventions
One year treatment with interferon/ribavirin and amantadine or placebo.
Sponsors
Dr. K.J. van Erpecum, hoofdonderzoeker
Prof. Dr. M. Samsom, hoofdonderzoker
UMC Utrecht
Huispostnummer F02.618
Postbus 85500
3508 GA Utrecht
Eligibility
Inclusion criteria
Inclusion criteria: 1. Anti-HCV positivity; >6 months; 2. ALT and/or AST elevation on at least once in the previous 6 months; 3. Positive HCV-RNA; 4. Liver biopsy within one year before the start of therapy in non-cirrhosis; In the case of known cirrhosis, liver biopsy is not necessary; 5. Intention to be treated and participate treatment; 6. Obtained written informed consent.
Exclusion criteria
Exclusion criteria: 1. Age 150 ìmol/L or > 1.70 mg/dl; 7. Haemoglobulin < 6.5 mmol/l or < 10.5 g/dl, white blood cell count < 2,5 x 109/L, neutrophil < 1,5 x 109/L, platelet count < 70 x 109/L; 8. HIV positivity; 9. Chemotherapy, systemical antiviral treatment during the 6 months prior to study entry; 10. Other serious disease (e.g. malignancy, uncontrolled myocardial disease or severe arythmias); 11. Active uncontrolled psychiatric disorders and suicidal leanings; 12. Patients with a history of uncontrolled seizure or other significant CNS dysfunction; 13. Any condition which in the opinion of the (co-)investigator might interfere with the evaluation of the study objectives.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Virological response at week 52 and 104. | — |
Contacts
Public ContactK.J. Erpecum, van
University Medical Center Utrecht (UMCU), F02.618, P.O. Box 85500
Outcome results
None listed